Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
On Tuesday, Stifel analysts maintained a Buy rating and a $35.00 price target for Oculis Holding AG (NASDAQ:OCS), currently trading at $17.58 with a market capitalization of $934 million. The company, which has seen an impressive 16% gain over the past week according to InvestingPro data, is drawing attention for its innovative research and development strategies. The analysts praised Oculis’s R&D Day presentation, which showcased a diverse portfolio of new treatments aimed at previously unaddressed eye and retinal conditions. These treatments are expected to streamline both regulatory and treatment pathways, including a new venture into the field of neuro-ophthalmology.
Oculis’s lead candidate, OCS-01, has finished enrolling participants for two pivotal studies in diabetic macular edema (DME), with results anticipated in the second quarter of 2026. This drug is designed to target patients who are newly diagnosed, a group that represents 67% of the DME population and is often not treated until their condition worsens.
The company has also made significant strides with licaminlimab, receiving approval from the FDA to proceed with pivotal studies for the treatment of dry eye disease (DED) in patients with TNFR1+ marker. This development is significant as it reduces the risk associated with the program and sets a precedent for precision medicine in the field.
Additionally, Oculis is advancing privosegtor as a neuroprotectant in acute optic neuritis (AON), non-arteritic anterior ischemic optic neuropathy (NAION), and multiple sclerosis (MS) relapse. Key opinion leaders (KOLs) regard privosegtor as one of the most promising neuroprotectants available, with the potential to prevent nerve damage in a range of ocular and neurological conditions.
In summary, Stifel analysts are optimistic about Oculis’s pipeline, considering it to be one of the most novel in the ophthalmology sector. They reiterated their Buy recommendation and a price target of $35, signaling confidence in the company’s future prospects. InvestingPro analysis shows the company maintains a "Fair" overall financial health score, with additional insights available through 8 more exclusive ProTips and comprehensive financial metrics.
In other recent news, Oculis Holding AG has completed patient enrollment for its Phase 3 DIAMOND-1 and DIAMOND-2 trials, evaluating the OCS-01 eye drops for diabetic macular edema (DME). These trials, involving over 800 patients across 119 global sites, aim to assess the efficacy and safety of OCS-01, with topline data expected in the second quarter of 2026. H.C. Wainwright has revised its price target for Oculis to $29, down from $30, while maintaining a Buy rating, following Oculis’s financial results for 2024, which included a net loss of CHF 85.8 million. Stifel analysts also reiterated a Buy rating with a $35 price target, citing positive results from the Phase 2 ACUITY trial for OCS-05/privosegtor, targeting acute optic neuritis. Oculis’s financial position remains stable, with cash and equivalents of $109 million at the end of 2024, supported by a recent $93 million financing round. The company is on track to submit a New Drug Application for OCS-01 by the first quarter of 2025. Additionally, interactions with the FDA have confirmed the development path for OCS-02 for dry eye disease, with further discussions planned for late 2025. Oculis plans to provide more updates on its clinical progress at an upcoming R&D Day.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.